Epidermolysis Bullosa - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2017, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 2, 9 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Almirall SA
Amryt Pharma plc
Anterogen Co Ltd
Berg LLC
CSL Ltd
Exicure Inc
Fibrocell Science Inc
GlaxoSmithKline Plc
Immusoft Corp
InMed Pharmaceuticals Inc
Karus Therapeutics Ltd
Mesoblast Ltd
ProQR Therapeutics NV
RegeneRx Biopharmaceuticals Inc
Scioderm Inc
Stratatech Corp
TransDerm Inc
WAVE Life Sciences Ltd
Epidermolysis Bullosa - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADP-31415 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
allantoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLO-ASC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birch bark extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCX-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INM-750 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KA-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QR-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
May 02, 2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
Apr 25, 2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
Apr 24, 2017: Amryt Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial for AP101 in EB
Apr 03, 2017: Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
Mar 28, 2017: Amryt Pharma: Phase 3 Clinical Trial for AP101 in EB
Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex
Mar 06, 2017: Amryt Pharma Announces AP101 trial discussions completed with FDA & EMA
Feb 27, 2017: RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
Feb 23, 2017: Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Feb 07, 2017: Amryt Pharma: Grant of patent in Japan for lead drug candidate, AP101 (Episalvan) for Treatment of Epidermolysis Bullosa
Jan 18, 2017: Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa
Jan 05, 2017: Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Dec 02, 2016: Amryt Pharma: €20m facility agreed with European Investment Bank
Nov 05, 2016: Abeona Therapeutics Honored with Partner in Progress Award from DEBRA of America
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H1 2017
Epidermolysis Bullosa - Pipeline by Almirall SA, H1 2017
Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H1 2017
Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H1 2017
Epidermolysis Bullosa - Pipeline by Berg LLC, H1 2017
Epidermolysis Bullosa - Pipeline by CSL Ltd, H1 2017
Epidermolysis Bullosa - Pipeline by Exicure Inc, H1 2017
Epidermolysis Bullosa - Pipeline by Fibrocell Science Inc, H1 2017
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H1 2017
Epidermolysis Bullosa - Pipeline by Immusoft Corp, H1 2017
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H1 2017
Epidermolysis Bullosa - Pipeline by Karus Therapeutics Ltd, H1 2017
Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H1 2017
Epidermolysis Bullosa - Pipeline by ProQR Therapeutics NV, H1 2017
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
Epidermolysis Bullosa - Pipeline by Scioderm Inc, H1 2017
Epidermolysis Bullosa - Pipeline by Stratatech Corp, H1 2017
Epidermolysis Bullosa - Pipeline by TransDerm Inc, H1 2017
Epidermolysis Bullosa - Pipeline by WAVE Life Sciences Ltd, H1 2017
Epidermolysis Bullosa - Dormant Projects, H1 2017
Epidermolysis Bullosa - Discontinued Products, H1 2017